Zymeworks Reports Preliminary Phase 1 Trial Results For Zanidatamab Zovodotin (ZW49) At European Society For Medical Oncology Annual Congress
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
Zymeworks Provides Corporate Update And Reports Second Quarter 2022 Financial Results
Zymeworks Announces Participation In Upcoming Investor Conferences
Zymeworks Announces Oral Presentation Of Data From Phase 1 Study Of Zanidatamab Zovodotin (ZW49) In Solid Cancers At European Society For Medical Oncology (ESMO) Congress 2022 In Paris
Zymeworks To Host Second Quarter Results Conference Call
Zymeworks Statement on U.S. Supreme Court Overturning Roe v. Wade
On June 24, 2022, the U.S. Supreme Court delivered a decision in Dobbs v. Jackson Women’s Health Organization that overturned the landmark 1973 Roe v. Wade ruling. This decision will have significant implications for women’s healthcare across the US and in many states where our colleagues, partner organizations and patients live and work. At Zymeworks, […]
Zymeworks Appoints Dr. Paul Moore As Chief Scientific Officer
Zymeworks Announces Participation In Upcoming Investor Conference
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
Zymeworks to Present Trials in Progress Poster for HERIZON-GEA-01 at ESMO GI
Zymeworks is pleased to announce the acceptance of an abstract for poster presentation at the European Society for Medical Oncology World Congress on Gastrointestinal Cancers (ESMO GI) taking place in Barcelona, Spain from June 29 to July 2, 2022. The Trials in Progress poster will review Zymeworks’ global Phase 3 study, HERIZON-GEA-01 (NCT05152147), which will […]
Zymeworks Announces Participation In Upcoming Investor Conferences
